Agenus Inc.

AGEN · United States

Share price · AGEN

$6.40-1.13 (-15.01%) 3M

close as of 2026-11-18 · 24h delayed · vol 880K (1.2x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when AGEN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 6 Nov 2026+11.0%
  2. 13 Jul 2026+82.7%
  3. 1 Jul 2026+11.4%
  4. 11 May 2026-14.7%
  5. 21 Apr 2026-11.5%
  6. 14 Apr 2026+13.7%
  7. 6 Apr 2026+13.2%
  8. 17 Mar 2026+21.3%
  9. 16 Jan 2026-9.2%
  10. 15 Jan 2026-21.4%

Share of unusual movement by asset

For each asset, the share of AGEN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Botensilimab
events and moves
132%
Balstilimab
events and moves
122%
Other company news (earnings, financing, releases naming no asset)—37%
Sessions with no dated event—59%

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
CTLA-4Monoclonal antibody
Non-Small Cell Lung CancerColorectal Cancer
Phase 2
PD-1Monoclonal antibody
Non-Small Cell Lung CancerCervical Cancer

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
September 2027 (1)
Balstilimab + BotensilimabPhase 2Metastatic Colorectal Cancer
Est. primary completion 2027-09 · NCT05608044 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

October 2026ApprovalBotensilimabArmenia grants the first marketing authorizations for botensilimab and balstilimab
AM, Ministry of Health of Armenia · Agenus Inc. · Source ↗
October 2026ApprovalBalstilimabArmenia grants the first marketing authorizations for botensilimab and balstilimab
AM, Ministry of Health of Armenia · Agenus Inc. · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$31M$12M$67M+ $20M short-term inv.—-$20M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$35M$15M$19M—-$31M operating cash flowreport ↗
2026-Q1$34M$12M$35M—-$36M operating cash flowreport ↗
2025-Q3$30M$24M$3.5M+ <$0.1M short-term inv.—-$15M operating cash flowreport ↗
2025-Q2$26M$27M$9.5M—-$20M operating cash flowreport ↗
2025-Q1$24M$22M$18M+ <$0.1M short-term inv.—-$26M operating cash flowreport ↗
2024-Q3$25M$41M$45M+ <$0.1M short-term inv.—-$53M operating cash flowreport ↗
2024-Q2$24M$37M$94M—-$38M operating cash flowreport ↗
2024-Q1$28M$44M$53M+ <$0.1M short-term inv.—-$38M operating cash flowreport ↗
2023-Q3$24M$51M$106M—-$65M operating cash flowreport ↗
2023-Q2$25M$59M$143M+ $15M short-term inv.—-$60M operating cash flowreport ↗
2023-Q1$23M$57M$165M+ $24M short-term inv.—-$59M operating cash flowreport ↗
2022-Q3$23M$46M$208M+ $9.9M short-term inv.—-$32M operating cash flowreport ↗
2022-Q2$21M$45M$228M+ $9.9M short-term inv.—-$43M operating cash flowreport ↗
2022-Q1$26M$42M$248M+ $15M short-term inv.—-$52M operating cash flowreport ↗
2021-Q3$253M$43M$257M+ $5.0M short-term inv.—$131M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$114M$79M$3.0M+ $0 short-term inv.$0.8M-$77M operating cash flowreport ↗

Agenus reported full-year 2025 revenue of $114.2M, up 10.4% YoY, with R&D spend of $79.34M, down 49.0% YoY. The company ended the period with $3M in cash and equivalents and reported a net loss of $3.08M, reflecting a quarterly net burn of $3.08M.

Business highlights centered on the BOT+BAL immunotherapy program: the Phase 3 BATTMAN registrational trial in refractory MSS metastatic colorectal cancer was initiated, and global early access programs expanded, generating initial program revenue of $4.2M from 200+ physician inquiries across 30+ countries. The Zydus collaboration closed with $91M in upfront capital, plus a $20M contingent payment triggered in March 2026, and clinical data included a 42% two-year overall survival and ~21-month median overall survival in heavily pretreated MSS mCRC patients.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$103M$156M$40M$58M-$158M operating cash flowreport ↗
2023-FY$156M$235M$76M$64M-$224M operating cash flowreport ↗
2022-FY$98M$187M$179M+ $15M short-term inv.—-$175M operating cash flowreport ↗
2021-FY$296M$179M$292M+ $15M short-term inv.—$10M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-01HARRISON THOMAS L · directorAward / grant4,443$6.89$31KForm 4
2026-10-01Wright Timothy · directorAward / grant (derivative)1,178.764——Form 4
2026-08-10ARMEN GARO H · director, See RemarksAward / grant (derivative)1,971,500——Form 4
2026-08-05Marcucci Marco Tullio · directorAward / grant (derivative)7,500——Form 4
2026-08-05Corvese Brian · directorAward / grant (derivative)100,000——Form 4
2026-08-05HARRISON THOMAS L · directorAward / grant (derivative)50,000——Form 4
2026-08-05Buell Jennifer · director, See RemarksAward / grant (derivative)200,000——Form 4
2026-08-05Hirsch Susan B · directorAward / grant (derivative)50,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 87 reporting institutions held 9.2M shares ($30.0M, 20.4% of shares outstanding).

#InstitutionSharesValue
1VANGUARD CAPITAL MANAGEMENT LLC1,440,232$4.8M
2VANGUARD PORTFOLIO MANAGEMENT LLC1,195,109$4.0M
3Siren, L.L.C.1,064,250$3.6M
4MARSHALL WACE, LLP688,203$2.3M
5BlackRock, Inc.545,662$1.8M
6GEODE CAPITAL MANAGEMENT, LLC348,395$1.2M
7MORGAN STANLEY295,821$988K
8RENAISSANCE TECHNOLOGIES LLC285,646$954K
9Man Group plc278,980$932K
10RAYMOND JAMES FINANCIAL INC239,554$800K
11UBS Group AG234,439$783K
12VANGUARD FIDUCIARY TRUST CO200,498$670K
13Connor, Clark & Lunn Investment Management Ltd.198,502$663K
14TWO SIGMA INVESTMENTS, LP170,922$571K
15PANAGORA ASSET MANAGEMENT INC163,148$545K